These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 31088111)

  • 1. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
    Bro T; Hägg S
    Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
    de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
    Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
    Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
    Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS; Muecke J
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 12-Month Safety and Efficacy Outcomes.
    Chang AA; Broadhead GK; Hong T; Joachim N; Syed A; Schlub TE; Toth L; Peto T; Zhu M
    Ophthalmic Res; 2015; 55(2):84-90. PubMed ID: 26637166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
    Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
    Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
    Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting.
    Fulcher C; Hazel CA; Pacey I; Ali H; Ghanchi FD
    Eur J Ophthalmol; 2020 May; 30(3):543-549. PubMed ID: 30935224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
    Zinkernagel MS; Wolf S; Ebneter A
    Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
    Heier JS; Wykoff CC; Waheed NK; Kitchens JW; Patel SS; Vitti R; Perlee L; Chu KW; Leal S; Asmus F; Son V; Schmelter T; Brown DM
    Ophthalmology; 2020 Feb; 127(2):211-220. PubMed ID: 31791663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.